French company Danone hasn't had much luck so far hawking its medical nutrition business--and bidder Fresenius may be set to walk away, Reuters reports. After talks reportedly stalled with tax inversion-minded Hospira ($HSP), the German drugmaker is now considering pulling out thanks to frustration with a long, complicated sales process. On the other hand, "it would be wrong to say Fresenius is not interested anymore," one source told the news service. Story | More